CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Aims: The purpose of this study is to determine if it is possible to safely reduce the total number of cycles of chemotherapy needed for Hodgkin lymphoma based on the patient's response during treatment as seen on positron emission tomography (PET) scan images. A PET scan is an imaging technique that can detect the possibility of active cancer.
Diagnosis: Bulky Stage I and II Classical Hodgkin Lymphoma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-030
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E2905: Randomized Phase III Trial Comparing The Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlemid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.
Aims: The purpose of this study is to compare the good and/or bad affects of a drug called lenalidomide on blood disorders when given alone or in combination with a drug called epoetin alfa. Epoetin alfa boosts the production of red blood cells. The drug lenalidomide makes young red blood cells more likely to be affected by the growth-promoting effects of epoetin alfa. This study aims to determine if the combination of treatment with epoetin alfa and lenalidomide is better than lenalidomide alone in improving red blood cell production and decreasing the need for blood transfusions in patients with MDS (myelodysplastic syndrome).
Diagnosis: Myelodysplastic Syndrome or Symptomatic Anemia
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH09-422
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E3A05: Ancillary Laboratory Protocol For Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders.
Aims: This is a laboratory study where patients may decide to contribute samples of blood and bone marrow which will be used to screen them for participation in treatment studies and may be used for future research of plasma cells disorders. Patients may choose to only participate in the screening portion of this study.
Diagnosis: Plasma Cell Disorders 
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH09-311
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E3903: Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders.
Aims: The purpose of this study is to determine the genetic make-up of a patient's disease in order to confirm that the treatment received is the best available. Treatment for blood disorders depends on the type of blood/bone marrow cells that are affected. In this study, blood samples will be collected so that the doctor can make sure that treatment is appropriate for a specific disease. Also, researchers want to gather samples (extra blood and bone marrow) to be used for future research on blood disorders.
Diagnosis: Leukemia and Other Blood Disorders
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH05-385
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CALGB 9665: The CALGB Leukemia Tissue Bank
Aims: The purpose of this study is to collect blood and tissue samples from patients with leukemia and myelodysplasia for the purpose of future research. This research is being done to better understand the causes of leukemia and myelodysplasia and to develop improved methods of diagnosis and treatment for these diseases.
Diagnosis: Leukemia or Myelodysplasia
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH04-248
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CALGB 8461: Cytogenetic Studies in Acute Leukemia
Aims: The purpose of this study is to determine if response to treatment is related to particular leukemia cell types. Researchers want to obtain samples of blood and bone marrow from patients with Acute Leukemia and Multiple Myeloma to study certain characteristics in the chromosomes (genetic material) of cells affected by this disease.
Diagnosis: Acute Leukemia and/or Multiple Myeloma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH04-247
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

TELESTO ICL670A2302: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Deferasirox in Patients with Myelodysplastic Syndromes (low/int-1 risk) and Transfusional Iron Overload (TELESTO)
Aims: Myelodysplastic Syndromes (MDS) are disorders of the bone marrow in which blood cells are not produced in sufficient quantities.  MDS can cause anemia, or a decrease in the number of red blood cells, which usually is treated through the use of blood transfusions. However, in many patients, this leads to a build-up of iron in the body called secondary iron overload.  Iron overload can lead to liver and heart damage.  Deferasirox is an oral medicine used to treat iron overload due to blood transfusions and has been approved by the US Food and Drug Administration for this purpose.  However, the benefit of excess iron removal with Deferasirox is not well established for patients with MDS. This study will evaluate patients with Myelodysplastic Syndrome who are treated with Deferasirox compared to MDS patients who take a placebo (pill that contains no medicine).
Diagnosis: Myelodysplastic Syndrome (MDS) patients who have had multiple blood transfusions 
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-165
Sponsor: Novartis Pharmaceuticals
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumuamb, Bortezomib (NSC #681239, IND#58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
Aims: The purpose of this study is to compare the effects of treatment with a combination of the drugs ofatumumab and bendamustine against treatment with a combination of the drugs ofatumumab, bendamustine, and bortezomib in patients with follicular lymphoma.  The combination of these drugs has not been approved for use in follicular lymphoma by the FDA.  However, these drugs are FDA-approved for certain types of cancers when used individually.
Diagnosis: Follicular Lymphoma
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH12-075
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CALGB 20202: Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Aims: The purpose of this study is to examine acute myeloid leukemia (AML) cells and chromosomes, genes and proteins within these cells. This may help researchers learn more about how to prevent, find, and treat cancer and other diseases. In some instances, this study will be necessary to determine eligibility for treatment on a CALGB clinical trial.
Diagnosis: Acute Myeloid Leukemia 
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH12-217
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Aims: The purpose of this study is to compare the effects, good and/or bad on you an dyour MDS or CMML, of adding either the drug lenalidomide or the drug vorinostat to the regular treatment drug azacitidine compared with receiving azacitidine alone.
Diagnosis: Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-161
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

S1001: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Aims: The purpose of this study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of still having active lymphoma and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma. IN this way, we hope to improve the cure rate for all patients while decreasing the side effects of treatment.
Diagnosis: Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Principal Investigator: David Grinblatt, M.D.
IRB Approval Number: EH13-343
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MM: The Multiple Myeloma Disease Registry
Aims: This research study is being done to learn more about multiple myeoma and its treatments. Researchers also want to better understand how multiple myeloma impacts the life of people living with multiple myeloma. This is an observational study, which means it is a study that does not prescibe research medication or require medical treatment. The purpose of this study is to collect information on your disease and medical treatment that your doctor is already collecting as part of your normal care.
Diagnosis: Multiple Myeloma (MM)
Principal Investigator: David Grinblatt, M.D.
IRB Approval Number: EH10-273
Sponsor: Celgene
Contact: Interested patients should contact the research coordinator Darin Chokdee at 847.570.2106
Open to Enrollment: Yes

Onyx/Clarion 2012-005: A Randomized, Open-Label Phase III Study of Carfilzomib, Melphalan, and Predisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Aims: The purpose of this study is to compare the safety and effectiveness of two sets of chemotherapy drugs in patients with newly diagnosed multiple myeloma. The first chemotherapy drug set combines and investigational drug called carfilzomib (Kyprolis®; Carfilzomib for Injection), with melphalan and prednisone (CMP treatment). The second set combines the drug bortezomib (Velcade®) with melphalan, prednisone (VMP treatment). Velcade is a drug that has been FDA approved to treat multiple myeloma and mantle cell lymphoma. 
Diagnosis: Multiple Myeloma (MM)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-396
Sponsor: Onyx/Clarion
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GSK: HOMER: OMB113676: Phase III Randomized, Open Label Study of Single Agent Ofatumumab vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Aims: The purpose of this study is to test the safety and effectiveness of a study drug called ofatumumab compared to a drug that is already approved to treat follicular lymphoma, named rituximab (also called Rituxan). Both of these agents are forms of the study drug known as monoclonal antibodies. They are proteins designed to attack specific targets and endhance the immune system's ability to control disease like lymphoma.
Diagnosis: Follicular Lymphoma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH13-448
Sponsor: GlaskoSmithkline (GSK)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

× Alternate Text